PTC Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1998-01-01
- Employees
- 1K
- Market Cap
- $2.7B
- Website
- http://www.ptcbio.com
- Introduction
PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company was founded by Allan Steven Jacobson and Stuart Walter Peltz on March 31, 1998 and is headquartered in Warren, NJ.
A Study of Sepiapterin in Participants With Phenylketonuria (PKU)
- First Posted Date
- 2024-03-08
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- PTC Therapeutics
- Target Recruit Count
- 56
- Registration Number
- NCT06302348
- Locations
- 🇺🇸
Indiana University, Indianapolis, Indiana, United States
An Extension Study to Evaluate the Long-Term Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD)
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- PTC Therapeutics
- Target Recruit Count
- 250
- Registration Number
- NCT06254482
- Locations
- 🇦🇹
Medical University Innsbruck, Innsbruck, Austria
🇦🇺Westmead Hospital, Westmead, Australia
🇨🇦The Ottawa Hospital, Parkinson's and Movement Disorders Clinic, Ottawa, Canada
A Study to Assess the Safety and Efficacy of Vatiquinone in Participants With Friedreich Ataxia
- First Posted Date
- 2022-08-25
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- PTC Therapeutics
- Target Recruit Count
- 140
- Registration Number
- NCT05515536
- Locations
- 🇺🇸
University of South Florida, Tampa, Florida, United States
🇺🇸UCLA, Los Angeles, California, United States
🇺🇸University of Iowa, Iowa City, Iowa, United States
A Study of Vatiquinone for the Treatment of Participants With Friedreich Ataxia
- First Posted Date
- 2022-08-03
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- PTC Therapeutics
- Target Recruit Count
- 5
- Registration Number
- NCT05485987
- Locations
- 🇺🇸
The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
A Study to Evaluate the Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD)
- First Posted Date
- 2022-05-03
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- PTC Therapeutics
- Target Recruit Count
- 252
- Registration Number
- NCT05358717
- Locations
- 🇩🇪
Charite University Medicine Berlin, Berlin, Germany
🇺🇸University of California, San Diego, La Jolla, California, United States
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
Study to Assess the Effects of PTC857 Treatment in Participants With Amyotrophic Lateral Sclerosis ALS
- Conditions
- Interventions
- First Posted Date
- 2022-04-27
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- PTC Therapeutics
- Target Recruit Count
- 307
- Registration Number
- NCT05349721
- Locations
- 🇪🇸
Unidad Neuromuscular. Servicio de Neurologia Hospital Universitari Vall d'Hebron, Barcelona, Spain
🇮🇹Maggiore della Carita University Hospital, Neurology department, ALS center, Novara, Italy
🇮🇹AOU Citta Della Salute e Scienza, Torino, Italy
A Study of Unesbulin in Participants With Advanced Leiomyosarcoma (LMS)
- Conditions
- Interventions
- First Posted Date
- 2022-03-08
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- PTC Therapeutics
- Target Recruit Count
- 360
- Registration Number
- NCT05269355
- Locations
- 🇺🇸
University of California, Los Angeles (UCLA) - Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Northwestern Memorial Hospital, Chicago, Illinois, United States
🇺🇸The Ohio State University (OSU), Columbus, Ohio, United States
A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial Disease
- First Posted Date
- 2022-02-01
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- PTC Therapeutics
- Target Recruit Count
- 100
- Registration Number
- NCT05218655
- Locations
- 🇺🇸
The Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Akron Children's Hospital, Akron, Ohio, United States
🇺🇸Children's Hospital of Philadelphia - CHOP, Philadelphia, Pennsylvania, United States
A Long-Term Safety Study of PTC923 in Participants With Phenylketonuria
- First Posted Date
- 2021-12-21
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- PTC Therapeutics
- Target Recruit Count
- 200
- Registration Number
- NCT05166161
- Locations
- 🇦🇺
The Queensland Children's Hospital, South Brisbane, Queensland, Australia
🇵🇱Pomorski Uniwersytet Medyczny w Szczecinie Centrum, Szczecin, Poland
🇺🇸University of Colorado and the Children's Hospital CO, Aurora, Colorado, United States
A Study of PTC923 in Participants With Phenylketonuria
- First Posted Date
- 2021-10-29
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- PTC Therapeutics
- Target Recruit Count
- 157
- Registration Number
- NCT05099640
- Locations
- 🇫🇷
Bretonneau Hospital - CHRU de Tours, Tours, Centre-Val De Loire, France
🇺🇸Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸Icahn School of Medicine at Mount Sinai (ISMMS), New York, New York, United States